The malleability of the epigenome has long been recognized as a unique opportunity for therapeutic intervention. Interest in targeting components of the epigenetic machinery for therapeutic gain had initially been aimed at chromatin modifying enzymes. However, advances in medicinal chemistry have now made it possible to exploit protein^protein interactions at the chromatin interface. Bromodomains (BRD) are a conserved motif used by a large number of chromatin-associated proteins to recognize and bind acetylated histone tails. Small molecules with high specificity for the Bromodomain and Extra Terminal family of proteins (BRD2, BRD3, BRD4 and BRDT) have recently been shown to have remarkable pre-clinical efficacy in various malignancies. These findings have provided the impetus for exploring other BRD proteins as novel targets in cancer therapy.
INTRODUCTION
The dawn of the genomic era has focused our attention on the central role of epigenetic regulators in cancer biology. It is now apparent that many of the components involved in the epigenetic regulation of gene expression, DNA repair and replication are commonly mutated in various cancers [1, 2] . Importantly, the plasticity of the epigenome lends itself well to therapeutic manipulation and as such there is now great interest in generating small molecules that are effective in modulating the activities of the various protagonists involved in controlling the epigenetic landscape.
A fundamental tenet in chromatin biology is that all components of the nucleosome are covalently modified and these modifications are dynamic entities that play an instructive role in various biological processes. Currently, there are four different DNA modifications and over 16 separate histone modifications described [2] . These modifications serve two main functions; they alter chromatin structure by enhancing or weakening the non-covalent interactions between histone-histone or histone-DNA and they provide an informative platform for the dynamic recruitment of chromatin modifying/remodelling enzymes that then establish local and global chromatin patterns. Whilst many of the proteins that control and interpret these modifications have been implicated in oncogenesis the subject of this review will focus on the bromodomain (BRD) proteins that bind acetylated lysine residues on histones. For a more comprehensive overview on cancer epigenetics, the reader is referred to several recent reviews [1] [2] [3] [4] [5] .
Histone acetylation is one of the best-studied histone modifications. It has been implicated in the control of gene expression, DNA repair and replication. Levels of acetylation are controlled by the competing activities of two enzymatic families: the histone acetyl transferases (HATs) and the histone deacetylases (HDACs). HATs catalyse the transfer of an acetyl group to the e-amino group of lysine side chains of a histone protein, whereas HDACs' function to remove it. Altered levels of histone acetylation are widely reported in various malignancies [6] and the pharmacological interference with the acetylation levels represents a promising approach for cancer therapy. A widely cited proof of principle for this approach is HDAC inhibitors which inactivate many of the enzymes that remove acetyl groups from acetylated lysines within histone and non-histone proteins [7] . In fact, HDAC inhibitors are currently used for the treatment of cutaneous T-cell lymphoma and are being assessed in clinical trials for the treatment of several other types of malignancies [8] [9] [10] . The addition of an acetyl group on histones serves two main purposes: first, it neutralizes the positive charge on lysine thus reducing the electrostatic interaction with the negatively charged DNA, relaxing the chromatin structure and facilitating the access of various chromatin associated proteins; second, it provides a binding site for proteins with specialized binding motifs that recognize this histone modification. The best characterized binding motif for lysine acetylation is the BRD.
BROMODOMAINS: STRUCTURE AND FUNCTION
BRDs are 110 amino acid modules that are highly conserved throughout evolution. They were first identified in the protein encoded by the D. melanogaster brahama gene. The BRD-containing protein family includes various transcriptional coregulators, chromatin modifying enzymes and nuclear scaffold proteins that are able to specifically recognize acetylated lysine residues on histone tails. BRD containing proteins can also bind acetylated lysine residues on non-histone proteins. For instance, it has been reported that BRD4 can bind acetylated lysines on the NF-kappaB subunit RelA [11] and similarly BRD3 has been shown to associate with acetylated GATA1 [12] .
The BRD structure consists of a left-handed bundle of four antiparallel alpha helices linked by two loop regions (Figure 1 ). The co-crystal structures of BRDs bound to acetyl-lysine containing peptides show that the acetylated lysine is first recognized in a hydrophobic pocket located between the two loops, which is formed by the most highly conserved residues. This includes an asparagine at the core of the binding site, which engages the acetyl-lysine via a hydrogen bond between its NH 2 group and the acetyl carbonyl oxygen atom of the acetylated lysine. At the entrance of the binding pocket, residues located in the two loop regions interact with residues adjacent to the acetylated lysine in the target sequence, thus further reinforcing the binding through hydrophobic and electrostatic interactions. Although the acetyl-lysine binding pocket for all BRDs is hydrophobic, there is considerable variation in the electrostatic interactions at the opening of the pocket among BRD families [13] . This variation determines the specificity of individual BRDs and provides the opportunity to both sub-classify BRD proteins into families and develop specific small molecules that are specifically targeted against certain families.
The human genome encodes 46 diverse proteins that contain a total of 61 BRDs structurally clustered into eight distinct subfamilies ( Figure 2 ). The first subfamily is comprised of a functionally diverse group of proteins that includes the HAT P300/ CBP-associated factor (PCAF). Indeed, it was the solution of the BRD structure of PCAF that demonstrated the ability of BRDs to bind to acetylated lysine's [14] . The Bromodomain and Extra Terminal (BET) proteins are grouped in the second subfamily and highly specific small molecule inhibitors of this family have recently emerged as promising therapeutic agents in inflammation and cancer [15] . Proteins within the fifth subfamily are structurally characterized by the presence of a methyl-lysine reader domain, the plant homeodomain (PHD) finger in tandem with a BRD. This tandem epigenetic reader module is necessary for the binding to chromatin and highlights an important theme in chromatin biology: the multivalent engagement of histone modifications by epigenetic reader proteins that contain more than one reader domain. Whilst an exhaustive description of the structural diversity of the various BRD families is beyond the scope of this review the reader is directed to an excellent and comprehensive review of this subject [16] .
From a functional perspective, most of the BRD containing proteins are integral members of larger multi-subunit chromatin complexes. These can be roughly grouped in three major categories: chromatin modifiers, chromatin readers and chromatin remodellers. The first group is composed of enzymes that possess the capacity to introduce modifications on chromatin, such as histone methylation (MLL) and histone acetylation (CREBBP/p300). The second group contains proteins that do not possess enzymatic activity on chromatin but can recruit general transcription factors or chromatin modifying complexes (BET). The third group is composed of proteins with ATPase activity able to remodel chromatin (SMARCA4).
In the histone acetyl-transferase complexes, the BRD component is generally responsible for anchoring the HATs complex to acetylated chromatin so allowing the spreading of acetylation on adjacent nucleosomes. Likewise, several chromatin remodelling complexes, which are ATP-dependent remodellers of DNA-histones interactions and nucleosome position, are recruited to their appropriate genomic location by the BRD proteins they contain. This localization then facilitates gene expression by improving access for the transcriptional machinery. BET proteins contain two BRDs at their amino terminal and an extra-terminal domain at their carboxyl terminal, which is also involved in protein-protein interactions. Whilst the tandem BRDs of the BET Figure 2 : Phylogenetic tree based on the structure of the human BRDs. The BRDs are grouped in eight families, each family is identified by a roman number. In cases where several bromodomains are present on a single protein they are differentiated by the number in brackets. Adapted from Filippakopoulos et al. [13] .
proteins localize them to acetylated histones, the ET domain interacts with various transcription factors or chromatin remodellers aiding the localization of these proteins to chromatin. It is also feasible that the two BRDs of the BET proteins bind multiple adjacent acetyl-lysine residues on the same nucleosome, on different nucleosomes or on adjacent non-nucleosomal proteins. The complete nuclear BET interactome has recently been defined and serves to highlight the broad functional diversity of these essential BRD proteins [17] .
BROMODOMAINS AS THERAPEUTIC TARGETS
The importance of transcriptional dysregulation as a sentinel event in the initiation and maintenance of oncogenesis has been well established. A wealth of literature describes the role that various transcription factors play in this process. The difficulty has been establishing a therapeutic strategy that negates the aberrant transcriptional programmes driven by these transcription factors. The recognition that many epigenetic regulators are either directly or indirectly co-opted to facilitate these oncogenic geneexpression programmes has opened untapped avenues for cancer therapeutics. A major focus in this arena is the opportunity to develop and deploy small molecules against epigenetic reader domains such as BRDs. Many of the BRD proteins play an integral role in the regulation of transcription via a direct association with transcription factors and/or the localization of chromatin modifying complexes. A further testament to the influence these proteins have in the oncogenic process is the fact that many of these proteins are recurrently mutated or aberrantly expressed in various malignancies ( Table 1) .
The BRD/histone interaction can be blocked by small molecules directed to the acetylated lysine recognizing pocket. These small molecules mimic the acetyl-lysine head group and interact with the conserved residues, while their lipophilic part interacts with the hydrophobic side chains of the binding site's residues [57] . Early NMR-based screening studies identified several compounds that were capable of selectively disrupting the acetyl-lysine BRD interaction [58, 59] . These findings established the principle of selective BRD inhibition and provided the impetus for the recent development of highly potent and selective inhibitors of the BET family of BRD proteins [17, 28, 60] . The stage is now set for the development of a range of structurally distinct medicinal compounds that selectively inhibit the functionally diverse set of BRD proteins. These inhibitors may offer a novel therapeutic paradigm in range of malignancies [15] .
CHROMATIN READERS
The BRD proteins that lack intrinsic chromatin modifying potential primarily function as scaffolds for transcription factors or other chromatin regulating factors. Exemplars of this group are the BET BRD proteins, which are epigenetic readers that recognize acetylated lysine residues on histone tails. The family includes four different proteins, BRD2, BRD3, BRD4 and BRDT and is characterized by the presence of two distinct BRDs at the N-terminal end of the protein. It is notable that members of the BET family are recurrently mutated or aberrantly co-opted in several cancers. For instance, BRD3 and BRD4 are involved in the pathognomonic chromosomal translocations seen in NUT midline carcinoma (NMC) [61] . In addition, BET proteins are part of transcriptional complexes that are essential for the initiation and maintenance of certain leukaemias. They are also associated with viral oncoproteins, such as the HPV E2 protein [62] . The important function of the BET proteins in gene regulation and their involvement in various cancers suggested that inhibitors of the BET BRDs maybe promising anti-cancer agents [15] . This led to the development of three different BET inhibitors: I-BET762, JQI and I-BET151. These drugs have been shown to be highly specific to the BET BRDs. They are cell permeable and able to displace the BET proteins from acetylated histones in a cellular context.
Translocations involving the mixed leukaemia gene (MLL) are the initiating event in a range of acute myeloid and lymphoid leukaemias. These diseases often share a common mechanism of transformation and are almost uniformly refractory to conventional therapies. A common feature of these translocations is the fusion of MLL gene with genes that code for members of the super elongation complex (SEC). The central role of transcriptional elongation in the pathogenesis of MLL leukaemia is further highlighted by the MLL mediated interaction with the polymerase associated factor complex (PAFc). Importantly, the functional integrity of both the SEC and PAFc has been shown to be Transcriptional regulator
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Transcriptional corepressor [56] critical for the malignant transformation by MLL fusions [63, 64] . Using a novel tripartite proteomic approach, Dawson et al. demonstrated that BRD3 and BRD4 are fundamental components of the PAFc and SEC complexes providing a therapeutic rationale for BET inhibitors in these leukaemia's [17] (Figure 3) . Moreover, using a complementary approach, Zuber et al. showed that the downregulation of BRD4 by RNAi strongly reduced the viability of MLL-AF9 leukaemias both in vitro and in vivo [65] . Both groups went on to demonstrate that chemically distinct but equally selective inhibitors of the BET BRD proteins showed excellent efficacy in inducing growth arrest and apoptosis in MLL cell lines. This effect is achieved by the downregulation of pivotal oncogenes, such as MYC and BCL2 ( Figure 3 ). These studies also showed the efficacy of BET inhibition in AML cell lines lacking MLL rearrangements, albeit at slightly higher concentrations to those seen in MLL-translocated leukaemias, suggesting that this therapeutic approach may be useful in different subtypes of AML and potentially in different haematopoietic malignancies [17, 65] . Indeed, in concurrent studies two other groups showed that BET inhibition is effective in Multiple Myeloma and Burkitt's lymphoma [66, 67] . Both these pathologies are characterized by an abnormal expression of MYC and the therapeutic effect shown by these studies was deemed to be mediated, at least in part, by the downregulation of MYC [66, 67] . Together, these studies suggest MYC as one of the main target genes for BET inhibition. Nevertheless, the identification of the BET protein interactome shows that these proteins are involved in a large number of nuclear regulatory complexes suggesting that the therapeutic effect in different malignancies may be driven by a variety of diverse molecular mechanisms. The tripartite motif (TRIM)-containing proteins are another family of epigenetic reader proteins that could be useful therapeutic targets in cancer. The TRIM proteins are characterized by the presence of a conserved N-terminal motif formed by a RING finger, one or two zinc-binding domains and a coiled-coil domain. These factors are involved in a range of homeostatic processes and have also been implicated in several diseases including cancer. The TRIM family is subdivided into 12 subgroups based on the C-terminal part of the protein. The TIF1 proteins, TRIM24 (TIF1a), TRIM 28 (TIF1b) and TRIM33 (TIF1g) constitute one of the 12 subgroups of the TRIM family and contain a PHD finger and a single BRD at their C-terminus. The presence of these epigenetic reader domains allows these factors to recognize and bind specific methylation/acetylation modifications on a single nucleosome and potentiate a specific transcriptional response.
TRIM24, the founding member of the TIF family, has been associated with the pathogenesis of several malignancies. The TRIM24-FGFR1 fusion is a rare but recurrent translocation observed in a subset of myeloproliferative diseases [68] . Other fusion proteins involving TRIM24 have also been observed in various solid cancers [51, 69] and overexpression of TRIM24 is observed in subset of breast cancers where it confers a poor prognosis [70] . Experimental evidence in murine models of hepatocellular carcinoma has suggested a tumour suppressor function for TRIM24 and TRIM33 and mechanistic insights have demonstrated a functional interaction between these factors and key regulatory proteins including p53 [71] , SMAD transcription factors [72] and oestrogen receptors [73] . Infact, TRIM24 has recently been shown to mediate an aberrant oestrogen response in breast cancer via a specific interaction with modified and unmodified residues on the tail of histone H3 [73] .
CHROMATIN REMODELLERS
Modifications of the nucleosome can directly influence the compaction state of chromatin by altering the affinity of the histone-DNA interaction. In addition to this, the active reorganization of nucleosome positioning is often necessary to initiate transcription. In mammals, four major complexes of chromatin remodellers have been identified: the switching defective/sucrose non-fermenting (SWI/SNF) family, the imitation SWI family, the nucleosome remodelling and deacetylation/Mi-2/chromodomain helicase DNA-binding family (NuRD) and the inositol requiring 80 family. These remodelling complexes are capable of both shifting and evicting nucleosomes. The energy obtained from the ATPase activity is used to destabilize the interaction between DNA and histones. The chromatin remodelling activity of the SWI/SNF complex in mammalian cells can induce both transcriptional activation and transcriptional repression. Activation is achieved by the creation of loops of open chromatin that are accessible to transcription factors, whilst repression is achieved by concentrating nucleosomes at specific genomic regions and reducing the accessibility of DNA to the transcriptional machinery.
The SWI/SNF complexes are formed by the physical interaction of 9-12 protein subunits. The core subgroup of proteins that are always present in the complex include SNF5, BAF170, BAF155 and one of the mutually exclusive ATPase subunits SMARCA4 or SMARCA2, both of which contain a BRD. The accessory subunits are often lineage and context specific and tailor the regulation and the targeting of the complexes. In mammalians two distinct subgroups of SWI/SNF complexes can be identified by the presence of specific accessory subunits. The BRG1-associated factor (BAF) complex, also known as SWI/SNF-A, is characterized by the presence of the ARID1A/B subunits; whilst the polybromo-BAF (pBAF) complex, also known as SWI/SNF-B is characterized by the presence of BAF180, BAF200 and BRD7. The BAF complex can associate with both SMARCA4 (BRG1) and SMARCA2 (BRM) catalytic subunits but the pBAF complex is almost exclusively associated with SMARCA4. In mammals, the expression of several components of the SWI/SNF complexes is tissue specific, generating variants of the remodelling complexes that direct cell fate by facilitating lineage-specific gene expression programmes.
Several members of the SWI/SNF complexes are involved in cancer. In particular, the core subunit SNF5 and the ATPase subunits SMARCA2 and SMARCA4 are often downregulated or deleted in variety of cancers suggesting a tumour-suppressor role for these complex members [74] .
The expression of BRG1 is markedly reduced in 20-50% of primary human lung cancers [75, 76] . However, experimental evidence would suggest that gene dosage and cellular context play a significant role in determining the functional outcome from pertubations in BRG1. BRG1 haploinsufficiency in lung cells was initially demonstrated to accelerate carcinogenesis induced by ethyl carbamate but interestingly homozygous deletion of BRG prevented the formation of lung tumours [77] . Furthermore, if the homozygous deletion of BRG1 is induced after the treatment with the carcinogen it now promotes carcinogenesis [77] . Further evidence to support the hypothesis that gene dosage is important is seen in a haploinsufficient murine model where one of the brg1 alleles is deleted. These mice develop mammary tumours that retain the expression of the second brg1 allele indicating that a residual ATPase activity is necessary for tumour cells [78] .
The wealth of genomic and functional information implicating the SWI/SNF complexes in cancer would suggest that aberrant chromatin localization via one of the many BRD containing proteins to facilitate oncogenic gene expression programmes is likely to be involved. Therefore, small molecules that specific perturb the BRD-mediated association with chromatin may find a therapeutic niche in certain malignancies.
CHROMATIN MODIFIERS
Several members of the BRD family are direct chromatin modifiers. These enzymes may use their BRD to bind to chromatin and deposit and spread new modifications on neighbouring nucleosomes facilitating specific biological outcomes.
An example of this group is the cyclic AMP response element-binding (CREB) protein (CBP) and the highly homologous p300, which are histone acetyltransferases and transcriptional cofactors that contain a single BRD [79] . CBP/p300 also function as a scaffold for various members of the transcriptional machinery and/or transcription factors [80, 81] . Together, CBP/p300 localize to acetylated chromatin via their BRD, modify chromatin through their HAT activity and recruit the transcriptional machinery to potentiate gene expression. CBP is also able to bind acetylated lysines on non-histone proteins, such as p53, and this interaction is required for the activation of the cyclin-dependent kinase inhibitor p21 [82] . These functions have led to many studies that have drawn associations with CBP/p300 activity and the development, maintenance or progression of cancer. In rare cases of acute myeloid leukaemia CBP, and less frequently p300, are found fused with the monocytic leukaemia zinc-finger protein (MOZ) or MLL [83] [84] [85] . When present, these fusions are often the initiating event in the transformation process. These proteins have also been ascribed an oncogenic function in prostate cancer [86] . Here, CBP and p300 function as cofactors of the androgen receptor (AR) and drive the progression of prostate cancer [87] . Interestingly, they are induced by androgen deprivation and can induce androgen-dependent genes in castrationresistant cancers even in the presence of very low AR levels [88] . Further evidence to support their oncogenic potential is derived from the observation that inhibition of the acetyltransferase activity of CBP-p300 induces apoptosis in prostate cancer cells [89] . In contrast to its reported oncogenic function, inactivating mutations of CBP have also been described in a range of haematological and solid malignancies [37, 36] . The functional consequences of these inactivating mutations have not been explored in depth but serve to highlight the fact that, like many chromatin regulators, CBP/P300 may act as oncogenes or tumour suppressors depending on the cellular context. As the BRD of CBP/ p300 serves to localize their activity at chromatin these could represent an exciting therapeutic target if applied in the correct context and malignancy.
CLINICAL APPLICATION
The exciting possibility of translating these novel epigenetic therapies into the clinical arena has already begun with the BET inhibitors. The results of these early stage clinical trials are eagerly awaited not only from an efficacy point of view but also from a toxicity perspective. Many of the proteins discussed earlier play a fundamental role in cellular homeostasis and as such one would expect that perturbation of their function might have detrimental effects in normal tissues. Interestingly, this prediction has not been a major issue thus far in the pre-clinical characterization of these compounds. Using the BET inhibitors as an example, in vitro studies with these compounds on mobilized haematopoietic stem cells show only a modest effect on their clonogenic capacity in comparison with the near complete inhibition observed in the leukaemia initiating cells [17, 65] . Similarly, in vivo studies with these compounds at doses that have significant anti-tumour activity does not led to widespread systemic toxicity as evidenced by a lack of significant anorexia, diarrhoea or a discernable nadir in blood counts [17, [65] [66] [67] . Nonetheless, it should be recognized that treatment with these compounds results in a reversible sterility consequent to the inhibition of BRDT [90, 91] . Whilst the pre-clinical characterization of these compounds is an imperative step in the process of clinical translation, these studies are limited by their scope and duration. The ultimate proof of clinical utility will be gleaned from the ensuing clinical trials in human subjects.
CONCLUDING REMARKS
The last decade has witnessed some of the most impressive advances in human biology. The advent of new technologies and innovative platforms has ushered us into the 'Omic' era, one that promises an unparalleled opportunity to tackle human disease. Whilst the fundamental principle in oncology, that cancer is a disease initiated and driven by genetic anomalies remains uncontested, we are now more than ever aware that this is not the whole story. Many of the hallmarks of cancer, such as malignant self-renewal, differentiation blockade, evasion of cell death and tissue invasiveness are profoundly influenced by changes in the epigenome. Moreover, unlike genomic aberrations, the plasticity of the epigenome provides the perfect milieu for therapeutic intervention. Recognition of these facts has led to a flood of interest in developing novel cancer therapeutics aimed at chromatin regulators. A testament to this progressive approach has been the FDA approval of DNA methyltransferase inhibitors and HDAC-I, which have already made a substantial clinical impact. The pre-clinical promise offered by inhibitors that specifically target the BRDs of BET proteins is a further paradigm shift in our ability to manipulate the epigenome for therapeutic gain. With improved technologies and the increasing interest of the scientific community the stage is now set to make some fundamental inroads into the fight against cancer.
Key Points
Targeting the epigenome is an emerging therapeutic paradigm in cancer biology. BRD containing proteins play a diverse role in regulating various biological processes. The normal cellular function of several BRD proteins is perturbed in the initiation and maintenance of various malignancies. Advances in structural biology and medicinal chemistry have enabled the development of specific small molecule inhibitors to BRD proteins. 
